Dr. Shruti Rakesh Tiwari, MD

Dr. Tiwari practices at Virginia Cancer Specialists in Fairfax, Virginia.

Dr. Tiwari's NPI, 1124346028, was assigned on May 17, 2010. Dr. Tiwari holds District of Columbia license MD045361.

Dr. Tiwari's primary practice is Virginia Cancer Specialists, at 3040 Williams Dr, Fairfax, VA 22031 in Fairfax County. The practice phone is (703) 280-5390.

Dr. Tiwari's primary practice is Virginia Cancer Specialists in Fairfax, Virginia. Dr. Tiwari is also affiliated with Inova Fair Oaks Hospital. The medical group on file is Virginia Cancer Specialists. Dmand AI also links Dr. Tiwari to 2 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tiwari practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Tiwari's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Tiwari is licensed in District of Columbia.

CMS data shows 27,447 Medicare services from Dr. Tiwari across 46 procedure codes in 2024, for 419 Medicare patients. Medicare paid $362,711 for them.

CMS counts 419 Medicare patients who saw Dr. Tiwari in 2024. The largest group is 65 to 74, with 186 patients. 75% of them have high cholesterol, and 72% have high blood pressure. 9% are also on Medicaid. Their average risk score is 1.79, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tiwari's median patient age at 61, with 83% women.

In 2024, Dr. Tiwari wrote 567 Medicare Part D claims for 135 patients. 81% of them were for generic drugs. CMS names the drug for 460 of them, across 8 drugs with 11 or more claims each, at $633,849 in total drug cost. In 2023, CMS named 334 claims across 9 drugs.

Dr. Tiwari accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tiwari as offering telehealth.

Dmand AI links 9 papers to Dr. Tiwari, published from 2015 to 2024. 2024 was the busiest year, with 3. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms and Receptor, ErbB-2. Dr. Tiwari's most frequent co-authors are Ami A. Chitalia, MD, Paula Raffin Pohlmann, MD and Nanette H. Bishopric, MD.

Dmand AI links Dr. Tiwari to 3 clinical trials, 2 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Breast Neoplasms and Breast Diseases.

CMS Open Payments shows 90 general payments to Dr. Tiwari from 19 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 39% of the total. AstraZeneca Pharmaceuticals LP paid the most, $3,150.